3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods

被引:0
作者
Zhu, YQ
Pei, JF
Liu, ZM
Lai, LH [1 ]
Cui, JR
Li, RT
机构
[1] Peking Univ, State Key Lab Struct Chem Stable & Unstabel Speci, Coll Chem & Mol Engn, Beijing 100871, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
关键词
3D-QSAR; CoMFA; CoMSIA; proteasome inhibitors; tripeptide aldehyde; drug design;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ubiquitin-proteasome pathway plays a crucial role in the regulation of many physiological processes and in the development of a number of major human diseases, such as cancer, Alzheimer's, Parkinson's, diabetes, etc. As a new target, the study on the proteasome inhibitors has received much attention recently. Three-dimensional quantitative structure activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) and comparative molecule similarity indices analysis (CoMSIA) techniques were applied to analyze the binding affinity of a set of tripeptide aldehyde inhibitors of 20S proteasome. The optimal CoMFA and CoMSIA models obtained for the training set were all statistically significant with cross-validated coefficients (q(2)) of 0.615, 0.591 and conventional coefficients (r(2)) of 0.901, 0.894, respectively. These models were validated by a test set of eight molecules that were not included in the training set. The predicted correlation coefficients (r(2)) of CoMFA and CoMSIA are 0.944 and 0.861, respectively. The CoMFA and CoMSIA field contour maps agree well with the structural characteristics of the binding pocket of beta 5 subunit of 20S proteasome, which suggests that the 3D-QSAR models built in this paper can be used to guide the development of novel inhibitors of 20S proteasome. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1483 / 1496
页数:14
相关论文
共 57 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] Proteasome inhibition: a novel approach to cancer therapy
    Adams, J
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S49 - S54
  • [3] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
    Adams, J
    Behnke, M
    Chen, SW
    Cruickshank, AA
    Dick, LR
    Grenier, L
    Klunder, JM
    Ma, YT
    Plamondon, L
    Stein, RL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) : 333 - 338
  • [4] Ubiquitin, cellular inclusions and their role in neurodegeneration
    Alves-Rodrigues, A
    Gregori, L
    Figueiredo-Pereira, ME
    [J]. TRENDS IN NEUROSCIENCES, 1998, 21 (12) : 516 - 520
  • [5] IDENTITY OF THE 19S PROSOME PARTICLE WITH THE LARGE MULTIFUNCTIONAL PROTEASE COMPLEX OF MAMMALIAN-CELLS (THE PROTEASOME)
    ARRIGO, AP
    TANAKA, K
    GOLDBERG, AL
    WELCH, WJ
    [J]. NATURE, 1988, 331 (6152) : 192 - 194
  • [6] The proteasome:: Paradigm of a self-compartmentalizing protease
    Baumeister, W
    Walz, J
    Zühl, F
    Seemuller, E
    [J]. CELL, 1998, 92 (03) : 367 - 380
  • [7] Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa
    Böhm, M
    Stürzebecher, J
    Klebe, G
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (03) : 458 - 477
  • [8] A PROTEIN CATALYTIC FRAMEWORK WITH AN N-TERMINAL NUCLEOPHILE IS CAPABLE OF SELF-ACTIVATION
    BRANNIGAN, JA
    DODSON, G
    DUGGLEBY, HJ
    MOODY, PCE
    SMITH, JL
    TOMCHICK, DR
    MURZIN, AG
    [J]. NATURE, 1995, 378 (6555) : 416 - 419
  • [9] Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues
    Cardozo, C
    Michaud, C
    Orlowski, M
    [J]. BIOCHEMISTRY, 1999, 38 (30) : 9768 - 9777
  • [10] Ubiquitin-mediated proteolysis in learning and memory
    Chain, DG
    Schwartz, JH
    Hegde, AN
    [J]. MOLECULAR NEUROBIOLOGY, 1999, 20 (2-3) : 125 - 142